Related Experiment Video
Updated: May 28, 2026
11:26
Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
Published on: September 21, 2017
Continuous dopaminergic stimulation: clinical aspects and experimental bases
Maria Cruz Rodriguez-Oroz1, Concepción Marin, Oriol de Fabregues
1Department of Neurology, Hospital Donostia, 20014 San Sebastian, Spain. macruz.rodriguezoroz@osakidetza.net
The Neurologist
|November 3, 2011
Summary
Continuous dopaminergic stimulation in Parkinson disease reduces motor complications. Experimental models help understand how pulsatile versus continuous drug delivery impacts basal ganglia function and informs new treatment strategies.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Pulsatile dopaminergic drug administration in Parkinson disease (PD) is linked to motor fluctuations and dyskinesias.
- Continuous dopaminergic stimulation (CDS) strategies aim to minimize these motor complications.
- Understanding the mechanisms differentiating pulsatile and continuous dopaminergic treatment is crucial for PD management.
Purpose of the Study:
- To elucidate the mechanisms underlying motor complications in Parkinson disease related to different dopaminergic drug delivery modes.
- To investigate how experimental models of parkinsonism can inform the development of continuous dopaminergic stimulation therapies.
- To explore the biochemical and molecular changes in the basal ganglia associated with continuous versus pulsatile dopaminergic stimulation.
Main Methods:
- Utilizing experimental models of parkinsonism to study motor complications.
- Analyzing biochemical and molecular changes in the basal ganglia in response to different dopaminergic stimulation patterns.
- Evaluating strategies for continuous drug delivery, including longer half-life drugs and alternative administration routes.
Main Results:
- Experimental models provide insights into motor complications from pulsatile dopamine replacement.
- Studies reveal biochemical and molecular adaptations in the basal ganglia under continuous stimulation.
- These models facilitate the identification of novel therapeutic approaches for stabilizing motor response.
Conclusions:
- Continuous dopaminergic stimulation is superior to pulsatile delivery in mitigating motor complications in Parkinson disease.
- Experimental models are valuable tools for understanding the neurobiological effects of different dopaminergic therapies.
- Further research using these models can lead to improved continuous dopaminergic stimulation strategies for Parkinson disease patients.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...